IC
GOSS icon

Ikarian Capital’s Gossamer Bio GOSS Stock Holding History

Ikarian Capital’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,100
Closed -$7.69K – 148
2023
Q1 		$7.69K Hold
6,100
– – ﹤0.01% 117
2022
Q4 		$13.2K Sell
6,100
-604,307
-99% -$4.98M ﹤0.01% 83
2022
Q3 		$7.31M Sell
610,407
-389,980
-39% -$4.84M 1.46% 23
2022
Q2 		$8.37M Buy
1,000,387
+225,072
+29% +$1.74M 1.53% 22
2022
Q1 		$6.73M Sell
775,315
-391,618
-34% -$3.78M 0.89% 32
2021
Q4 		$13.2M Sell
1,166,933
-185,000
-14% -$2.2M 1.97% 13
2021
Q3 		$17M Buy
1,351,933
+303,550
+29% +$2.79M 1.2% 16
2021
Q2 		$8.51M Hold
1,048,383
– – 0.69% 42
2021
Q1 		$9.7M Hold
1,048,383
– – 0.33% 71
2020
Q4 		$10.1M Buy
1,048,383
+465,889
+80% +$4.59M 0.45% 52
2020
Q3 		$7.23M Sell
582,494
-121,505
-17% -$1.61M 0.52% 46
2020
Q2 		$9.15M Buy
+703,999
New +$8.85M 0.73% 46

Other funds holding GOSS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Ikarian Capital's GOSS Position: Q2 2023 in Review

Ikarian Capital sold out of Gossamer Bio (GOSS) in Q2 2023, closing a stake of 6,100 shares — an estimated $7.69K sold.

Ikarian Capital first reported a position in GOSS in Q2 2020 and held it in 12 quarters. The position peaked at $17M in Q3 2021. 99 funds tracked by Wall St. Rank hold GOSS as of Q2 2023.

  • Ikarian Capital reported no remaining Gossamer Bio position as of Q2 2023 after selling out during the quarter.
  • Ikarian Capital sold 6,100 Gossamer Bio shares in Q2 2023, an estimated $7.69K.
  • Ikarian Capital first reported a position in Gossamer Bio in Q2 2020 and held it in 12 quarters.
  • Ikarian Capital's Gossamer Bio position peaked at $17M in Q3 2021.
  • 99 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2023.

Based on Ikarian Capital's 13F filing for Q2 2023, filed 14 Aug 2023.